A meta-review of 23 studies, including two randomized controlled trials, six prospective studies, and 15 retrospective studies, found that rituximab was effective in 63% of patients with chronic inflammatory demyelinating polyneuropathy, 48% of those with anti-myelin-associated glycoprotein neuropathy, and 96% of those with autoimmune nodopathy [9]. Here, MAG is linked to chronic inflammatory demyelinating polyradiculoneuropathy.